US6419927B1
(en)
|
1981-09-08 |
2002-07-16 |
Anthony Cerami |
Method for reducing adverse effects of a human 70kDa mediator which results from endotoxin stimulation of macrophages
|
US6309640B1
(en)
|
1981-09-08 |
2001-10-30 |
The Rockefeller University |
Lipoprotein lipase suppression by endotoxin-induced mediator (shock assay)
|
US5700466A
(en)
*
|
1981-09-08 |
1997-12-23 |
The Rockefeller University |
Method of ameliorating or preventing septic shock using a monoclonal antibody specific to cachectin/tumor necrosis factor
|
GB2233559B
(en)
*
|
1988-03-11 |
1992-03-04 |
Celltech Ltd |
Antibodies for use in antilymphocyte antibody therapy
|
DE3823804A1
(de)
*
|
1988-07-14 |
1990-01-18 |
Basf Ag |
Neutralisation der in vitro und in vivo toxischen eigenschaften von tnf-(alpha) durch monoklonale antikoerper und den davon abgeleiteten fragmenten
|
NZ229922A
(en)
*
|
1988-07-18 |
1992-04-28 |
Chiron Corp |
Monoclonal antibodies specifically binding cachectin (tumor necrosis factor) and compositions
|
EP0355067A1
(en)
*
|
1988-08-19 |
1990-02-21 |
Celltech Limited |
Pharmaceutical products for anti-neoplastic therapy
|
DE10399036I1
(de)
†
|
1989-08-07 |
2004-04-01 |
Peptide Technology Ltd |
Bindeligande für Tumornekrosisfaktor.
|
US20030225254A1
(en)
*
|
1989-08-07 |
2003-12-04 |
Rathjen Deborah Ann |
Tumour necrosis factor binding ligands
|
US5959087A
(en)
*
|
1989-08-07 |
1999-09-28 |
Peptide Technology, Ltd. |
Tumour necrosis factor binding ligands
|
US5998378A
(en)
*
|
1989-08-16 |
1999-12-07 |
Chiron Corporation |
Compositions for the inhibition of TNF hormone formation and uses thereof
|
US5843693A
(en)
*
|
1989-08-16 |
1998-12-01 |
Chiron Corporation |
Assay method for screening for inhibitors of proTNF conversion
|
US6586222B1
(en)
|
1989-08-16 |
2003-07-01 |
Chiron Corporation |
Recombinant PR-3 and compositions thereof
|
EP0487610B1
(en)
*
|
1989-08-16 |
2000-02-09 |
Chiron Corporation |
Prohormone cleavage site blocking antibody
|
GB8921123D0
(en)
*
|
1989-09-19 |
1989-11-08 |
Millar Ann B |
Treatment of ards
|
US6713610B1
(en)
*
|
1990-01-12 |
2004-03-30 |
Raju Kucherlapati |
Human antibodies derived from immunized xenomice
|
US7192584B2
(en)
*
|
1991-03-18 |
2007-03-20 |
Centocor, Inc. |
Methods of treating psoriasis with anti-TNF antibodies
|
US6277969B1
(en)
|
1991-03-18 |
2001-08-21 |
New York University |
Anti-TNF antibodies and peptides of human tumor necrosis factor
|
AU668864B2
(en)
*
|
1991-03-18 |
1996-05-23 |
Centocor Inc. |
Chimeric antibodies specific for human tumor necrosis factor
|
US20040120952A1
(en)
*
|
2000-08-07 |
2004-06-24 |
Centocor, Inc |
Anti-TNF antibodies and peptides of human tumor necrosis factor
|
US6284471B1
(en)
*
|
1991-03-18 |
2001-09-04 |
New York University Medical Center |
Anti-TNFa antibodies and assays employing anti-TNFa antibodies
|
US5919452A
(en)
*
|
1991-03-18 |
1999-07-06 |
New York University |
Methods of treating TNFα-mediated disease using chimeric anti-TNF antibodies
|
ATE172880T1
(de)
*
|
1992-08-28 |
1998-11-15 |
Bayer Ag |
Verwendung von monoklonalen anti-tnf-antikörpern für die behandlung von bakteriellen meningitiden
|
US20050255104A1
(en)
*
|
1993-01-29 |
2005-11-17 |
Centocor, Inc. |
Methods of treating psoriasis using anti-TNF receptor fusion proteins
|
US5626843A
(en)
*
|
1993-02-26 |
1997-05-06 |
Advanced Biotherapy Concepts, Inc. |
Treatment of autoimmune diseases, including AIDS, by removel of interferons, TNFs and receptors therefor
|
US5888511A
(en)
*
|
1993-02-26 |
1999-03-30 |
Advanced Biotherapy Concepts, Inc. |
Treatment of autoimmune diseases, including AIDS
|
NZ278607A
(en)
*
|
1994-02-07 |
1999-05-28 |
Knoll Ag |
Use of tnf antagonists for treating disorders involving elevated serum levels of il-6 wherein the serum levels are 500pg/ml or above
|
DE4409513C1
(de)
*
|
1994-02-07 |
1995-10-19 |
Knoll Ag |
Verwendung von anti-TNF-Antikörpern als Arzneimittel zur Behandlung von Erkrankungen mit einem erhöhten Interleukin-6 Serumspiegel
|
WO1995024501A1
(en)
|
1994-03-07 |
1995-09-14 |
Cetus Oncology Corporation |
Compositions for the inhibition of tnf formation and uses thereof
|
US6090382A
(en)
|
1996-02-09 |
2000-07-18 |
Basf Aktiengesellschaft |
Human antibodies that bind human TNFα
|
CN103275221B
(zh)
|
1996-02-09 |
2016-08-17 |
艾伯维生物技术有限公司 |
结合人TNFα的人抗体
|
US7608262B2
(en)
*
|
1996-02-16 |
2009-10-27 |
The Kennedy Institute Of Rheumatology |
Methods of preventing or treating thrombosis with tumor necrosis factor antagonists
|
WO1998024893A2
(en)
*
|
1996-12-03 |
1998-06-11 |
Abgenix, Inc. |
TRANSGENIC MAMMALS HAVING HUMAN IG LOCI INCLUDING PLURAL VH AND Vλ REGIONS AND ANTIBODIES PRODUCED THEREFROM
|
US20020031513A1
(en)
*
|
1997-11-24 |
2002-03-14 |
Shamir Leibovitz |
Method and pharmaceutical composition for inhibiting premature rapture of fetal membranes, ripening of uterine cervix and preterm labor in mammals
|
AU756677B2
(en)
*
|
1999-03-02 |
2003-01-23 |
Centocor Inc. |
Anti-TNFalpha antibodies in therapy of asthma
|
AU771015B2
(en)
*
|
1999-03-18 |
2004-03-11 |
Celgene Corporation |
Substituted 1-oxo- and 1,3-dioxoisoindolines and their use in pharmaceutical compositions for reducing inflammatory cytokine levels
|
DE60037750T2
(de)
*
|
1999-10-06 |
2009-01-08 |
Abbott Gmbh & Co. Kg |
Zusammensetzung enthaltend einen tnf-alpha inhibitor und einen integrin alphavbeta3 rezeptorantagonist
|
US20090081234A1
(en)
*
|
2000-08-07 |
2009-03-26 |
George Heavner |
Anti-tnf antibodies, compositions, methods and uses for treatment of depression and related conditions
|
UA81743C2
(uk)
|
2000-08-07 |
2008-02-11 |
Центокор, Инк. |
МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
|
US6902734B2
(en)
|
2000-08-07 |
2005-06-07 |
Centocor, Inc. |
Anti-IL-12 antibodies and compositions thereof
|
US20060018907A1
(en)
*
|
2000-08-07 |
2006-01-26 |
Centocor, Inc. |
Anti-TNF antibodies and peptides of human tumor necrosis factor
|
US7288390B2
(en)
|
2000-08-07 |
2007-10-30 |
Centocor, Inc. |
Anti-dual integrin antibodies, compositions, methods and uses
|
US20110195063A1
(en)
*
|
2000-08-07 |
2011-08-11 |
Centocor, Inc. |
Methods of Treating Ankylosing Spondylitis Using Anti-TNF Antibodies and Peptides of Human Tumor Necrosis Factor
|
US20050249735A1
(en)
*
|
2000-08-07 |
2005-11-10 |
Centocor, Inc. |
Methods of treating ankylosing spondylitis using anti-TNF antibodies and peptides of human tumor necrosis factor
|
CA2439852A1
(en)
*
|
2001-03-02 |
2002-09-12 |
Christine Dingivan |
Methods of preventing or treating inflammatory or autoimmune disorders by administering integrin alphav beta3 antagonists
|
CA2385745C
(en)
|
2001-06-08 |
2015-02-17 |
Abbott Laboratories (Bermuda) Ltd. |
Methods of administering anti-tnf.alpha. antibodies
|
TWI334439B
(en)
*
|
2001-08-01 |
2010-12-11 |
Centocor Inc |
Anti-tnf antibodies, compositions, methods and uses
|
WO2003086458A1
(en)
|
2002-04-12 |
2003-10-23 |
Medimmune, Inc. |
Recombinant anti-interleukin-9 antibodies
|
US20040009172A1
(en)
*
|
2002-04-26 |
2004-01-15 |
Steven Fischkoff |
Use of anti-TNFalpha antibodies and another drug
|
US20030206898A1
(en)
|
2002-04-26 |
2003-11-06 |
Steven Fischkoff |
Use of anti-TNFalpha antibodies and another drug
|
CA2490409A1
(en)
|
2002-06-28 |
2004-01-08 |
Centocor, Inc. |
Mammalian ch1 deleted mimetibodies, compositions, methods and uses
|
CN102755646A
(zh)
|
2002-07-19 |
2012-10-31 |
艾博特生物技术有限公司 |
TNF α相关疾病的治疗
|
US20040033228A1
(en)
|
2002-08-16 |
2004-02-19 |
Hans-Juergen Krause |
Formulation of human antibodies for treating TNF-alpha associated disorders
|
MY150740A
(en)
|
2002-10-24 |
2014-02-28 |
Abbvie Biotechnology Ltd |
Low dose methods for treating disorders in which tnf? activity is detrimental
|
CN100434440C
(zh)
|
2002-12-02 |
2008-11-19 |
阿布格尼克斯公司 |
针对肿瘤坏死因子的抗体及其用途
|
US7101978B2
(en)
*
|
2003-01-08 |
2006-09-05 |
Applied Molecular Evolution |
TNF-α binding molecules
|
KR101224235B1
(ko)
|
2003-04-11 |
2013-01-25 |
메디뮨 엘엘씨 |
재조합 il9 항체 및 그의 용도
|
US20040229878A1
(en)
*
|
2003-05-13 |
2004-11-18 |
Depuy Spine, Inc. |
Transdiscal administration of specific inhibitors of P38 kinase
|
US7344716B2
(en)
|
2003-05-13 |
2008-03-18 |
Depuy Spine, Inc. |
Transdiscal administration of specific inhibitors of pro-inflammatory cytokines
|
BRPI0410331A
(pt)
|
2003-05-13 |
2006-05-30 |
Depuy Spine Inc |
método para tratar doença de disco degenerativa
|
US8273347B2
(en)
*
|
2003-05-13 |
2012-09-25 |
Depuy Spine, Inc. |
Autologous treatment of degenerated disc with cells
|
US7553827B2
(en)
*
|
2003-08-13 |
2009-06-30 |
Depuy Spine, Inc. |
Transdiscal administration of cycline compounds
|
US7429378B2
(en)
*
|
2003-05-13 |
2008-09-30 |
Depuy Spine, Inc. |
Transdiscal administration of high affinity anti-MMP inhibitors
|
US8361467B2
(en)
*
|
2003-07-30 |
2013-01-29 |
Depuy Spine, Inc. |
Trans-capsular administration of high specificity cytokine inhibitors into orthopedic joints
|
UA89481C2
(uk)
|
2003-09-30 |
2010-02-10 |
Центокор, Инк. |
Еритропоетинові міметичні шарнірно-серцевинні міметитіла людини, композиції, способи та застосування
|
US8895540B2
(en)
*
|
2003-11-26 |
2014-11-25 |
DePuy Synthes Products, LLC |
Local intraosseous administration of bone forming agents and anti-resorptive agents, and devices therefor
|
US7435799B2
(en)
*
|
2004-01-08 |
2008-10-14 |
Applied Molecular Evolution |
TNF-α binding molecules
|
KR20070004078A
(ko)
*
|
2004-03-31 |
2007-01-05 |
센토코 인코포레이티드 |
인간 glp-1 모방체, 조성물, 방법 및 용도
|
TWI439284B
(zh)
*
|
2004-04-09 |
2014-06-01 |
Abbvie Biotechnology Ltd |
用於治療TNFα相關失調症之多重可變劑量療法
|
US7351739B2
(en)
*
|
2004-04-30 |
2008-04-01 |
Wellgen, Inc. |
Bioactive compounds and methods of uses thereof
|
GB0414054D0
(en)
|
2004-06-23 |
2004-07-28 |
Owen Mumford Ltd |
Improvements relating to automatic injection devices
|
US7393662B2
(en)
*
|
2004-09-03 |
2008-07-01 |
Centocor, Inc. |
Human EPO mimetic hinge core mimetibodies, compositions, methods and uses
|
US20060083741A1
(en)
*
|
2004-10-08 |
2006-04-20 |
Hoffman Rebecca S |
Treatment of respiratory syncytial virus (RSV) infection
|
AU2005299355A1
(en)
|
2004-10-27 |
2006-05-04 |
Medimmune, Llc |
Modulation of antibody specificity by tailoring the affinity to cognate antigens
|
PA8672101A1
(es)
|
2005-04-29 |
2006-12-07 |
Centocor Inc |
Anticuerpos anti-il-6, composiciones, métodos y usos
|
KR101465456B1
(ko)
|
2005-05-16 |
2014-11-27 |
애브비 바이오테크놀로지 리미티드 |
미란성 다발관절염의 치료를 위한 tnf 억제제의 용도
|
JP2009501006A
(ja)
|
2005-06-30 |
2009-01-15 |
セントカー・インコーポレーテツド |
抗il−23抗体、組成物、方法および用途
|
JP5645361B2
(ja)
*
|
2005-08-02 |
2014-12-24 |
エクスバイオテク インコーポレーティッド |
IL−1α自己抗体を用いた血管障害の診断、処置、および予防
|
US20070041905A1
(en)
*
|
2005-08-19 |
2007-02-22 |
Hoffman Rebecca S |
Method of treating depression using a TNF-alpha antibody
|
CA2925307C
(en)
|
2005-08-30 |
2019-12-03 |
Intrexon Actobiotics Nv |
Novel treatment of chronic enterocolitis
|
TWI424161B
(zh)
|
2005-11-01 |
2014-01-21 |
Abbvie Biotechnology Ltd |
利用生物標記診斷關節黏連脊椎炎之方法及組合物
|
PL1971366T3
(pl)
|
2005-12-29 |
2015-01-30 |
Janssen Biotech Inc |
Ludzkie przeciwciała skierowane przeciw IL-23, kompozycje, sposoby i zastosowanie
|
EP3088410A3
(en)
*
|
2006-04-05 |
2016-12-28 |
AbbVie Biotechnology Ltd |
Antibody purification
|
EP2666472A3
(en)
|
2006-04-10 |
2014-04-02 |
Abbott Biotechnology Ltd |
Uses and compositions for treatment of psoriatic arthritis
|
US9605064B2
(en)
|
2006-04-10 |
2017-03-28 |
Abbvie Biotechnology Ltd |
Methods and compositions for treatment of skin disorders
|
EP2666478A3
(en)
|
2006-04-10 |
2014-10-22 |
AbbVie Biotechnology Ltd |
Uses and compositions for treatment of psoriasis
|
US20080118496A1
(en)
*
|
2006-04-10 |
2008-05-22 |
Medich John R |
Uses and compositions for treatment of juvenile rheumatoid arthritis
|
US20090317399A1
(en)
*
|
2006-04-10 |
2009-12-24 |
Pollack Paul F |
Uses and compositions for treatment of CROHN'S disease
|
EP2010214A4
(en)
*
|
2006-04-10 |
2010-06-16 |
Abbott Biotech Ltd |
USES AND COMPOSITIONS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS
|
US20080131374A1
(en)
*
|
2006-04-19 |
2008-06-05 |
Medich John R |
Uses and compositions for treatment of rheumatoid arthritis
|
US20110008282A1
(en)
*
|
2006-05-15 |
2011-01-13 |
Xbiotech, Inc. |
IL-1alpha immunization induces autoantibodies protective against atherosclerosis
|
ES2374845T3
(es)
*
|
2006-05-22 |
2012-02-22 |
Xbiotech, Inc |
Tratamiento de cáncer con anticuerpos anti-il-1.
|
EP2043711A4
(en)
|
2006-06-30 |
2017-08-30 |
AbbVie Biotechnology Ltd |
Automatic injection device
|
CA2657581A1
(en)
|
2006-07-11 |
2008-01-17 |
Roy C. Levitt |
Rhinosinusitis prevention and therapy with proinflammatory cytokine inhibitors
|
US20080014285A1
(en)
*
|
2006-07-13 |
2008-01-17 |
Di Mauro Thomas M |
Method of treating neurodegenerative brain disease with a composite comprising superparamagnetic nanoparticles and a therapeutic compound
|
JP2010500360A
(ja)
|
2006-08-10 |
2010-01-07 |
アルボア コーポレーション |
炎症性サイトカイン阻害剤による下気道炎症疾患の局所療法
|
EP2684895A1
(en)
|
2006-10-27 |
2014-01-15 |
AbbVie Biotechnology Ltd |
Crystalline anti-hTNFalpha antibodies
|
NZ598881A
(en)
|
2007-03-29 |
2013-11-29 |
Abbvie Inc |
Crystalline anti-human il-12 antibodies
|
JP5575636B2
(ja)
|
2007-05-07 |
2014-08-20 |
メディミューン,エルエルシー |
抗icos抗体ならびに、腫瘍、移植および自己免疫疾患の治療におけるその使用
|
EP2171451A4
(en)
|
2007-06-11 |
2011-12-07 |
Abbott Biotech Ltd |
METHOD FOR TREATING JUVENILIAN IDIOPATHIC ARTHRITIS
|
MX2010001488A
(es)
*
|
2007-08-08 |
2010-03-01 |
Abbott Lab |
Composiciones y metodos para cristalizar anticuerpos.
|
US20090038182A1
(en)
*
|
2007-08-09 |
2009-02-12 |
Lans Maris J |
Footwear with built-in scale
|
US20090162351A1
(en)
*
|
2007-12-21 |
2009-06-25 |
Depuy Spine, Inc. |
Transdiscal administration of inhibitors of p38 MAP kinase
|
US8986696B2
(en)
*
|
2007-12-21 |
2015-03-24 |
Depuy Mitek, Inc. |
Trans-capsular administration of p38 map kinase inhibitors into orthopedic joints
|
WO2009083246A1
(en)
|
2007-12-31 |
2009-07-09 |
Bayer Schering Pharma Aktiengesellschaft |
Antibodies to tnf alpha
|
WO2009090189A1
(en)
*
|
2008-01-15 |
2009-07-23 |
Abbott Gmbh & Co.Kg |
Powdered protein compositions and methods of making same
|
EP3085773B1
(en)
*
|
2008-05-30 |
2020-03-18 |
XBiotech, Inc |
Uses of il-1 alpha antibodies
|
EP2326347A4
(en)
*
|
2008-09-12 |
2013-03-06 |
Xbiotech Inc |
TARGETING PATHOGENIC MONOCYTES
|
US8415291B2
(en)
*
|
2008-10-31 |
2013-04-09 |
Centocor Ortho Biotech Inc. |
Anti-TNF alpha fibronectin type III domain based scaffold compositions, methods and uses
|
EP2358392B1
(en)
|
2008-11-12 |
2019-01-09 |
MedImmune, LLC |
Antibody formulation
|
WO2010127146A1
(en)
|
2009-04-29 |
2010-11-04 |
Abbott Biotechnology Ltd |
Automatic injection device
|
CN104634955B
(zh)
|
2009-10-26 |
2016-09-14 |
雀巢产品技术援助有限公司 |
检测抗-tnf药物和自身抗体的试验
|
BR112012014710A2
(pt)
|
2009-12-15 |
2017-07-25 |
Abbott Biotech Ltd |
botão de ignição aperfeiçoado para dispositivo de injeção automática
|
JP2013517330A
(ja)
|
2010-01-20 |
2013-05-16 |
トーラックス インコーポレイテッド |
抗ilt5抗体およびilt5結合抗体断片
|
EP2525822B1
(en)
|
2010-01-20 |
2017-05-10 |
Merck Sharp & Dohme Corp. |
Immunoregulation by anti-ilt5 antibodies and ilt5-binding antibody fragments
|
DK2582391T3
(en)
|
2010-06-18 |
2019-01-21 |
Xbiotech Inc |
ARTHRITIS TREATMENT
|
KR20160062200A
(ko)
|
2010-08-23 |
2016-06-01 |
엑스바이오테크, 인크. |
종양성 질병들에 대한 치료
|
CA2815026C
(en)
|
2010-10-18 |
2018-11-20 |
Nestec S.A. |
Methods for determining anti-drug antibody isotypes
|
AR084210A1
(es)
*
|
2010-12-08 |
2013-05-02 |
Abbott Lab |
PROTEINAS DE UNION AL TNF-a
|
EP2667918B1
(en)
|
2011-01-24 |
2017-03-01 |
AbbVie Biotechnology Ltd |
Automatic injection devices having overmolded gripping surfaces
|
KR101702339B1
(ko)
|
2011-01-24 |
2017-02-03 |
애브비 바이오테크놀로지 리미티드 |
주사기로부터 니들 실드의 제거 및 자동 주사 디바이스들
|
DK2676137T3
(en)
|
2011-02-17 |
2015-01-19 |
Nestec Sa |
TESTS TO DETECT AUTO ANTIBODIES FOR ANTI-TNF PHARMACEUTICALS
|
CN102675460B
(zh)
|
2011-02-28 |
2015-08-19 |
珠海市丽珠单抗生物技术有限公司 |
抗肿瘤坏死因子α的人源化抗体
|
US8658171B2
(en)
|
2011-02-28 |
2014-02-25 |
Livzon Mabpharm Inc. |
Humanized anti-TNFα antibodies
|
US9724409B2
(en)
|
2011-04-01 |
2017-08-08 |
Xbiotech, Inc. |
Treatment of inflammatory skin disease
|
WO2012149197A2
(en)
|
2011-04-27 |
2012-11-01 |
Abbott Laboratories |
Methods for controlling the galactosylation profile of recombinantly-expressed proteins
|
AU2012278802B2
(en)
|
2011-07-06 |
2015-11-26 |
Société des Produits Nestlé S.A. |
Assays for detecting neutralizing autoantibodies to biologic therapy with TNF alpha
|
CN103906536A
(zh)
|
2011-09-23 |
2014-07-02 |
埃克斯生物科技公司 |
恶病质治疗
|
BR112014009810A2
(pt)
*
|
2011-10-24 |
2017-04-25 |
Abbvie Inc |
imunoligantes biespecíficos dirigidos contra tnf e il-17
|
JP2014534218A
(ja)
*
|
2011-10-24 |
2014-12-18 |
アッヴィ・インコーポレイテッド |
Tnfを標的とする免疫結合剤
|
WO2013158279A1
(en)
|
2012-04-20 |
2013-10-24 |
Abbvie Inc. |
Protein purification methods to reduce acidic species
|
US9181572B2
(en)
|
2012-04-20 |
2015-11-10 |
Abbvie, Inc. |
Methods to modulate lysine variant distribution
|
US9067990B2
(en)
|
2013-03-14 |
2015-06-30 |
Abbvie, Inc. |
Protein purification using displacement chromatography
|
WO2013176754A1
(en)
|
2012-05-24 |
2013-11-28 |
Abbvie Inc. |
Novel purification of antibodies using hydrophobic interaction chromatography
|
US9512214B2
(en)
|
2012-09-02 |
2016-12-06 |
Abbvie, Inc. |
Methods to control protein heterogeneity
|
CA2883272A1
(en)
|
2012-09-02 |
2014-03-06 |
Abbvie Inc. |
Methods to control protein heterogeneity
|
US9545441B2
(en)
|
2012-09-18 |
2017-01-17 |
Xbiotech, Inc. |
Treatment of diabetes
|
CA2905010A1
(en)
|
2013-03-12 |
2014-09-18 |
Abbvie Inc. |
Human antibodies that bind human tnf-alpha and methods of preparing the same
|
WO2014159579A1
(en)
|
2013-03-14 |
2014-10-02 |
Abbvie Inc. |
MUTATED ANTI-TNFα ANTIBODIES AND METHODS OF THEIR USE
|
WO2014151878A2
(en)
|
2013-03-14 |
2014-09-25 |
Abbvie Inc. |
Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
|
US9017687B1
(en)
|
2013-10-18 |
2015-04-28 |
Abbvie, Inc. |
Low acidic species compositions and methods for producing and using the same using displacement chromatography
|
WO2014151901A1
(en)
|
2013-03-14 |
2014-09-25 |
Abbvie Inc. |
Improvement of mammalian cell culture performance through surfactant supplementation of feed media
|
CA2899308C
(en)
|
2013-03-14 |
2017-04-18 |
Abbvie Inc. |
Low acidic species adalimumab compositions and uses thereof
|
CA2899449A1
(en)
|
2013-03-14 |
2014-10-02 |
Abbvie Inc. |
Low acidic species compositions and methods for producing the same using displacement chromatography
|
PL2970980T3
(pl)
|
2013-03-15 |
2019-01-31 |
Janssen Biotech, Inc |
Sposoby wytwarzania kontrolujące zawartość C-końcowej lizyny, galaktozy i kwasu sjalowego w rekombinowanych białkach
|
WO2015051293A2
(en)
|
2013-10-04 |
2015-04-09 |
Abbvie, Inc. |
Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
|
US9085618B2
(en)
|
2013-10-18 |
2015-07-21 |
Abbvie, Inc. |
Low acidic species compositions and methods for producing and using the same
|
US8946395B1
(en)
|
2013-10-18 |
2015-02-03 |
Abbvie Inc. |
Purification of proteins using hydrophobic interaction chromatography
|
US9181337B2
(en)
|
2013-10-18 |
2015-11-10 |
Abbvie, Inc. |
Modulated lysine variant species compositions and methods for producing and using the same
|
WO2015073884A2
(en)
|
2013-11-15 |
2015-05-21 |
Abbvie, Inc. |
Glycoengineered binding protein compositions
|
WO2015198320A1
(en)
|
2014-06-24 |
2015-12-30 |
Insight Biopharmaceuticals Ltd. |
Methods of purifying antibodies
|
WO2016004197A1
(en)
|
2014-07-03 |
2016-01-07 |
Abbvie Inc. |
Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using cobalt
|
US20160185848A1
(en)
|
2014-07-09 |
2016-06-30 |
Abbvie Inc. |
Methods for modulating the glycosylation profile of recombinant proteins using sugars
|
SG11201704200SA
(en)
|
2014-12-05 |
2017-06-29 |
Nestec Sa |
Indirect homogeneous mobility shift assays for the detection of biologics in patient samples
|
EP3078675A1
(en)
|
2015-04-10 |
2016-10-12 |
Ares Trading S.A. |
Induction dosing regimen for the treatment of tnf alpha mediated disorders
|
US10465003B2
(en)
|
2016-02-05 |
2019-11-05 |
Janssen Biotech, Inc. |
Anti-TNF antibodies, compositions, methods and use for the treatment or prevention of type 1 diabetes
|
JOP20190162A1
(ar)
|
2016-12-30 |
2019-06-27 |
Biocad Joint Stock Co |
تركيبة صيدلانية مائية من جسم مضاد لـ tnf? أحادي النسيلة معاود الارتباط الجيني
|
KR20190113858A
(ko)
|
2017-01-30 |
2019-10-08 |
얀센 바이오테크 인코포레이티드 |
활성 건선성 관절염의 치료를 위한 항-tnf 항체, 조성물, 및 방법
|
WO2018147915A1
(en)
|
2017-02-07 |
2018-08-16 |
Janssen Biotech, Inc. |
Anti-tnf antibodies, compositions, and methods for the treatment of active ankylosing spondylitis
|
EP3582813A4
(en)
|
2017-02-16 |
2020-12-30 |
XBiotech, Inc |
TREATMENT OF SUPPURATIVE HIDRADENITIS
|
MX2021008537A
(es)
|
2019-01-15 |
2021-11-12 |
Janssen Biotech Inc |
Composiciones de anticuerpos anti-tnf y métodos para el tratamiento de la artritis idiopática juvenil.
|
CA3127748A1
(en)
|
2019-01-23 |
2020-07-30 |
Janssen Biotech, Inc. |
Anti-tnf antibody compositions for use in methods for the treatment of psoriatic arthritis
|
KR20210142002A
(ko)
|
2019-03-14 |
2021-11-23 |
얀센 바이오테크 인코포레이티드 |
항-tnf 항체 조성물을 생성하기 위한 제조 방법
|
EA202192505A1
(ru)
|
2019-03-14 |
2022-03-29 |
Янссен Байотек, Инк. |
Способы получения композиций антитела к фно
|
JP2022524860A
(ja)
|
2019-03-14 |
2022-05-10 |
ヤンセン バイオテツク,インコーポレーテツド |
抗tnf抗体組成物を産生するための方法
|
AU2020279987A1
(en)
|
2019-05-23 |
2021-11-18 |
Janssen Biotech, Inc. |
Method of treating inflammatory bowel disease with a combination therapy of antibodies to IL-23 and TNF alpha
|
CN113939531A
(zh)
|
2019-06-03 |
2022-01-14 |
詹森生物科技公司 |
用于治疗银屑病关节炎的抗tnf抗体组合物和方法
|
AU2020288404A1
(en)
|
2019-06-03 |
2022-02-03 |
Janssen Biotech, Inc. |
Anti-TNF antibodies, compositions, and methods for the treatment of active Ankylosing Spondylitis
|
WO2020263450A1
(en)
|
2019-06-25 |
2020-12-30 |
Procisedx Inc. |
Detection of anti-tnf alpha drug biologics and anti-drug antibodies
|
WO2021028752A1
(en)
|
2019-08-15 |
2021-02-18 |
Janssen Biotech, Inc. |
Anti-tfn antibodies for treating type i diabetes
|
CA3203308A1
(en)
|
2020-11-30 |
2022-06-02 |
Enigma Biointelligence, Inc. |
Non-invasive assessment of alzheimer's disease
|
CN117440967A
(zh)
|
2020-12-09 |
2024-01-23 |
怡诺安有限公司 |
抗OX40L抗体、抗OX40L/抗TNFα双特异性抗体及其用途
|
EP4367137A1
(en)
|
2021-07-09 |
2024-05-15 |
Janssen Biotech, Inc. |
Manufacturing methods for producing anti-tnf antibody compositions
|
EP4367136A1
(en)
|
2021-07-09 |
2024-05-15 |
Janssen Biotech, Inc. |
Manufacturing methods for producing anti-tnf antibody compositions
|